Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanirole Versus Placebo or Ropinirole in Patients With Early Parkinson's Disease.

NCT00036218 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00036218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00036218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanirole Versus Placebo or Ropinirole in Patients With Early Parkinson's Disease.
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2001
Completion date
April 30, 2003
Enrollment
600
Sites
102

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease